ADMETatlas: an online database of peptide ADMET evidence toward peptide therapeutic development
Nucleic Acids Research · 13.11.2026
DOI: 10.1093/nar/gkag1147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 13.11.2026. Verfasst von Jiacai Yi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, P. R. China. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Science and Technology Major Project of the Ministry of Science and Technology of China, Innovative Drug Research and Development National Science and Technology Major Project.
Abstract (Originalsprache)
Peptide therapeutics are expanding rapidly, yet poor permeability and limited in vivo stability still decide whether a candidate reaches the clinic. Judging these properties is difficult, because one sequence can be studied as different molecular forms or products, and reported values carry different experimental contexts. Despite the continuous accumulation of measurements of peptide absorption, distribution, metabolism, excretion, and toxicity (ADMET), few open-access resources keep each value attached to the material tested and its assay context. Herein, we present ADMETatlas, a curated peptide ADMET, safety, and developability database. Currently, ADMETatlas contains 39 641 measurements at 17 measured end points across 37 467 canonical peptide identities, 110 drug products, and 10 computed descriptors. Each measurement retains its value, unit, formal end point, assay context, and primary reference. Peptide identities, molecular forms, and products are cross-linked at the resolution each source supports. In addition to browsing and retrieval, a developability module profiles single candidates and compares several side by side. Applications to GLP-1 receptor agonists and polymyxin B show how route and formulation change the reading of peptide pharmacokinetics. We hope that ADMETatlas will prove useful in evidence-based peptide optimization and condition-aware modeling. ADMETatlas is freely available, without registration, at https://admetatlas.scbdd.com/.
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, P. R. China.
- Faculty of Computer Science and Artificial Intelligence, Shenzhen University of Advanced Technology, Shenzhen, Guangdong 518107, P. R. China.
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, P. R. China.
ORCID-Profile: Jiacai Yi, Yao Tian, Aiping Lyu, Dongsheng Cao
Förderung
- National Natural Science Foundation of China
- National Science and Technology Major Project of the Ministry of Science and Technology of China
- Innovative Drug Research and Development National Science and Technology Major Project
- Young Scientists Fund of the Natural Science Foundation of Hunan Province of China
- Key Program of the Natural Science Foundation of Hunan Province of China
- Postgraduate Cross-Disciplinary Innovation Incubation Program of Xiangya School of Medicine, Central South University
- Young Elite Scientists Sponsorship Program
- Frontier Interdisciplinary Direction of Intelligent Biomanufacturing, Central South University
Zitieren
APA
Yi, J., Tian, Y., Deng, Y., Gu, X., Fu, X., Jiang, D., Lyu, A., & Cao, D. (2026). ADMETatlas: an online database of peptide ADMET evidence toward peptide therapeutic development. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag1147
Vancouver
Yi J, Tian Y, Deng Y, Gu X, Fu X, Jiang D, et al. ADMETatlas: an online database of peptide ADMET evidence toward peptide therapeutic development. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag1147
BibTeX
@article{Yi2026,
author = {Yi, Jiacai and Tian, Yao and Deng, Youchao and Gu, Xinyu and Fu, Xiangzheng and Jiang, Dejun and Lyu, Aiping and Cao, Dongsheng},
title = {ADMETatlas: an online database of peptide ADMET evidence toward peptide therapeutic development},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkag1147}
}
EUVIMED